Search Results

Terry Kenakin’s Applying Pharmacology to Drug Discovery course.

Ho, ho, ho, GPCR elves! As the year wraps up, we're thrilled to present the final edition of the GPCR Weekly Newsletter for 2024! As researchers, we all understand the importance of data in driving meaningful discoveries  and advancing our experiments.   At Dr. GPCR, we believe the same principle applies to building a better experience  for our online community.   We’d love to hear your thoughts on our website and its features  so that we can continue to support your work and foster collaborations in the GPCR field.   Your feedback  will guide us in tailoring resources , tools , and content to meet your needs better and help fuel your research. Thank you for sharing your perspective and helping us shape the future of the Dr. GPCR ecosystem! Best, Yamina & the Dr. GPCR Team This Week’s Highlights: Congratulations to Andrew Tobin for an incredible week filled with prestigious events, including receiving the British Pharmacological Society Vane Medal and switching on the Christmas lights at the University of Glasgow Advanced Research Centre! Activation of the proton-sensing GPCR, GPR65 on fibroblast-like synoviocytes contributes to inflammatory joint pain Luke A Pattison , Rebecca H Rickman , Graham Ladds , Ewan St John Smith , et al. Attention, everyone! This is your last chance before the curtain closes: Classified GPCR News will be accessible only to VIP members next year! Indeed, all the details below will be limited to Premium Members . Don't miss out—upgrade now to keep up with your GPCR updates! Classified GPCR News  Let’s dive into the   Classified GPCR News from December 9th to 15th, 2024 Industry News When science meets serendipity: How accidental discoveries could revolutionise women’s health Seven unanswered questions about blockbuster weight-loss drugs Transforming Drug Discovery: Insights from Viva Biotech's GPCR and TPD Structural Biology Platforms GPCR Events, Meetings, and Webinars December 10 - 12, 2024 | Pharmacology 2024 January 13 - 16, 2025 | PepTalk 2025 January 25 - 29, 2025 | SLAS 2025 February 15 - 16, 2025 | Structural and Functional Approaches in GPCR Drug Discovery February 15 - 19, 2025 | BPS 2025 February 16 - 21, 2025 | Harnessing the Power of Advanced Multimodal Approaches to GPCR Drug Discovery March 12 - 14, 2025 | NextGen Biomed 2025 March 25 - 28, 2025 | 10th German Pharm-Tox Summit April 1 - 5, 2025 | XXIII GEM Meeting in 2025 April 3 - 6, 2025 | ASPET 2025 April 14 - 17, 2025 | 20th Drug Discovery Chemistry April 24 - 27, 2025 | American Physiology Summit 2025 April 25 - 30, 2025 | AACR Annual Meeting 2025 May 12 - 15, 2025 | PEGS 2025 May 20 - 22, 2025 | SLAS Europe 2025 June 16 - 19, 2025 | BIO International Convention 2025 July 12 - 17, 2026 | 20th World Congress of Basic and Clinical Pharmacology GPCR Jobs GPCR Molecular Pharmacologist Scientist - Biology Scientist I Cell Biology - Tectonic Therapeutic Senior Principal Scientist, Medicinal Chemistry PhD fellowship in GPCR mechanosensing Senior Scientist, GPCR Pharmacology Research Associate - Professor Graeme Milligan Postdoc in Molecular Pharmacology - The Hauser Group Postdoctoral Scholar – iPSC in cardiac and endothelial cell function Protein Biochemist/Structural Biologist GPCR Activation and Signaling Activation of the proton-sensing GPCR, GPR65 on fibroblast-like synoviocytes contributes to inflammatory joint pain Regulation of the chemokine receptors CXCR4 and ACKR3 by receptor activity-modifying proteins Single-cell transcriptomics of vomeronasal neuroepithelium reveals a differential endoplasmic reticulum environment amongst neuronal subtypes Methods & Updates in GPCR Research High-throughput optimisation of protein secretion in yeast via an engineered biosensor Optimized vector for functional expression of the human bitter taste receptor TAS2R14 in HEK293 cells Reviews, GPCRs, and more The role of the endocannabinoid system in the pathogenesis and treatment of epilepsy Become a Premium Member! Get your 5-day free trial TODAY!

Kenakin. Kenakin walks through a cannabinoid modulator that increases agonist binding while reducing signaling Kenakin frames this as a transformation between distinct protein species—illustrated conceptually as Kenakin’s case studies demonstrate that these observations can be reconciled within structured models Kenakin, monthly AMAs where specific data can be interrogated, and an on-demand library built around

Kenakin walks through this as a living system , showing how GPCRs exist in multiple conformations and Allosteric Interactions Only in Terry’s Corner 🎬 Plus New: Lesson Trailers   Curious about Terry’s Corner Kenakin     💎 $2999/year — one conference cost = 12 months of expert training  Premium Dr. That’s where Terry’s Corner changes the game. Subscribe to The Kenakin Brief  today ➤

Kenakin reveals how decision-making on early safety hinges on the ability to pinpoint liabilities—such Kenakin highlights the definitive role of patch clamp assays and how high-throughput adaptations have Kenakin clarifies that both direct hepatotoxic effects and conditional toxicities, such as those driven Kenakin demonstrates how mechanistic assays allow for early warning, ensuring that compounds prone to ’s Corner Terry’s Pharmacology Corner delivers weekly in-depth lectures by Dr.

. 👉 Unlock Irreversible Drugs —  Only in Terry’s Corner! Kenakin  will get released next month, featuring real questions from discovery scientists tackling enzyme Kenakin Content trusted by biotech, pharma, and academia 💎 $2999/year — one conference cost = a full Kenakin with your own enzyme or GPCR interaction puzzles. Subscribe to The Kenakin Brief  today ➤

Kenakin’s answers. Kenakin  noted, it wasn’t designed. Kenakin reveals  the substrate strategy needed for credible DDI assessment. Kenakin reveals  how teams choose between slow-off and true irreversible strategies. Why Terry’s Corner Give You The GPCR Pharmacology Insights You Need Terry’s Corner gives discovery scientists

Terry's Corner - New Course on Pharmacologic Models The latest Terry’s Corner unlocks clinical forecasting Kenakin. I wish Dr.

This week Terry's Corner unlocks a simple lever that separates signal from storytelling, moving programs Terry's Corner – Assay Volume Control in GPCR Drug Discovery This week in Terry’s Corner, you’ll learn 🎬 Plus New: Lesson Trailers   Curious about Terry’s Corner before committing? Kenakin every last Thursday of the month at 12pm EST 7-day free trial to explore the corner   💎 $2999 Kenakin. I wish Dr.

Terry’s Corner: Schild Analysis — Why It Matters Most assays show a clean rightward shift and we assume Kenakin breaks down why Schild analysis remains the gold standard for verifying true competition — and Premium Members get 50%+ discount  when they join Terry’s Corner. Kenakin is a leading expert in the field. Kenakin is a masterful teacher and communicator.”

Terry Hébert. This session with Terry Hébert will cover how patient-derived induced pluripotent stem cells (iPSCs), Kenakin is a leading expert in the field. Kenakin is a masterful teacher and communicator. — Dr. GPCR Course Attendee About Dr. GPCR Dr. Premium members access the full Masterclass library, weekly curated publications, live sessions, and the Terry

Nicole (Nicki) Perry-Hauser is now available What a fun chat! 📹Would you like to see the video?

Unlock “Kinetics: Advanced Applications” Only in Terry’s Corner Why Terry’s Corner Most pharmacology That’s where Terry’s Corner changes the game. experience Whether you’re validating assays, refining kinetic models, or deciding which leads to advance, Terry Subscribe to The Kenakin Brief  today ➤

Kenakin’s latest   lecture delivers exclusive, real-world insight designed to equip you to move beyond Kenakin’s kinetic insights help you translate assay readouts into actionable knowledge that keeps your But as Kenakin shows in this lecture, the reality is more nuanced, and mastering drug binding kinetics Kenakin’s lecture guides you through key questions that should shape your decision-making process: Are Kenakin gives you clear, practical guidance on when to look deeper and how to extract meaningful, operational

Unlock “Statistical Analysis” now Only in Terry’s Corner Why Terry’s Corner Your work demands clarity Terry’s Corner is designed to give you the edge. pharmacology experience Whether you’re validating assays, refining models, or deciding which leads to advance, Terry Subscribe to The Kenakin Brief today ➤ #ttest #ANOVA #poweranalysis #curvecomparison #ftest #assayvalidation

This week in Terry's Corner you'll learn how model-based thinking helps you determine a drug’s mechanism Take the example Terry highlights: an agonist curve with a rightward shift and elevated baseline. Unlock “Mechanism of Action” now Only in Terry’s Corner   Why Terry’s Corner When early choices determine Terry’s Corner is designed to give you the edge. Subscribe to The Kenakin Brief today ➤

Terry's Corner – How Enzyme Inhibition Shapes Every Discovery Program Every molecule meets an enzyme This week’s Terry’s Corner reframes inhibition not as background theory—but as a design lens for smarter Kenakin — October 30, 12 PM EST Bring your toughest pharmacology questions and join Dr. Kenakin live. Each session shapes next month’s lessons—so your challenges guide the content. Kenakin Trusted insights across biotech, pharma, and academia 💎 $2,999/year — one conference cost =

This week, Terry’s Corner takes you beyond curve shapes into the kinetic and mechanistic realities that Terry's Corner - Demystifying Antagonism: The Key to Precision Drug Discovery Understanding the nuances Kenakin’s expert guidance provides a clear framework for distinguishing these mechanisms and avoiding Premium Members get 50%+ discount when they join Terry’s Corner. Keywords: GPCR, drug discovery, pharmacology, antagonism, competitive, non-competitive, Terry's Corner

Terry illustrates this with classic β-receptor partial agonists, showing how heart rate set-points under Terry’s Corner exists to fix that blind spot. Why Terry’s Corner Most pharmacology training freezes at equilibrium snapshots. Subscribe to The Kenakin Brief today ➤

Terry’s Corner: GPCR Pharmacology Insights That Prevent Real Drug Discovery Failures Discovery collapses Kenakin’s AMA made the central point unmistakable: GPCR systems constantly reshape ligand behavior through Premium Members get 67% discount when they join Terry’s Corner in 2025 Sharpen your interpretation skills

This session with Terry Hébert will examine how iPSC-derived cardiomyocytes , organoid systems , and Sign up to the Kenakin Brief Newsletter ➤ Quick Links Antibody validation continues to constrain GPCR Kenakin — a course that defines affinity, efficacy, orthosteric versus allosteric binding, and kinetics

Terry's Corner – Orthosteric vs. This week in Terry's Corner, we focuse on the distinction between orthosteric and allosteric mechanisms overdose risk without sacrificing meaningful efficacy. 🎬 Plus New: Lesson Trailers   Curious about Terry Kenakin     💎 $2999/year — one conference cost = 12 months of expert training  Premium Dr.

Terry’s Pharmacology Corner is built around that reality. take place: Thursday, February 26th at 12:00 PM EST You are invited to submit questions in advance to: terry Why Terry’s Pharmacology Corner Mechanistic understanding evolves. Terry’s Pharmacology Corner provides a structured environment for that evolution: Weekly advanced pharmacology

Terry's Corner – Designing Drugs That Anticipate Physiological Pushback Most GPCR programs don’t fail This week’s Terry’s Corner  exposes the unseen physiological “opponents” your molecule faces—and how

Terry W. Moore, was most definitely a success.

While these signaling pathways are highly interconnected, they can also be regulated independently (Kenakin Kenakin, T. (2019). Biased receptor signaling in drug discovery.

In: Kenakin TP, editor A Pharmacology Primer (Sixth Edition). Kenakin TP. Kenakin TP. Kenakin T. The mass action equation in pharmacology. Kenakin T. Biased Receptor Signaling in Drug Discovery.

Kenakin and Hoare .

Kenakin and Hoare.

Kenakin and Hoare on '   Applying Pharmacology to Drug Discovery ' and ' Advanced Data Analysis for GPCR